Evidence map›Paper›PMID 31165274›Full record

ReviewTopics in current chemistry (Cham)2019

In the Search of Glycoside-Based Molecules as Antidiabetic Agents.

Aleksandra Pałasz, Dariusz Cież, Bartosz Trzewik, Katarzyna Miszczak, Grzegorz Tynor, Bartłomiej Bazan

Open access · hybridAbstract readReview
In one paragraph

Review in Topics in current chemistry (Cham), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 57 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. InSaudi journal of biological sciences · 2023
    Article
  6. Recent Advances on Natural Aryl-Molecules (Basel, Switzerland) · 2022
    Review
  7. Article
  8. Azobenzene as Antimicrobial Molecules.Molecules (Basel, Switzerland) · 2022
    Review
  9. Article
  10. Article
  11. Article
  12. Synthesis of spMolecules (Basel, Switzerland) · 2021
    Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Aleksandra PałaszDepartment of Organic Chemistry, Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387, Kraków, Poland. palasz@chemia.uj.edu.pl.ORCID http://orcid.org/0000-0002-7952-2826
Dariusz CieżDepartment of Organic Chemistry, Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387, Kraków, Poland.
Bartosz TrzewikDepartment of Organic Chemistry, Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387, Kraków, Poland.
Katarzyna MiszczakDepartment of Organic Chemistry, Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387, Kraków, Poland.
Grzegorz TynorDepartment of Organic Chemistry, Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387, Kraków, Poland.
Bartłomiej BazanDepartment of Organic Chemistry, Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387, Kraków, Poland.
Jagiellonian University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review is an effort to summarize recent developments in synthesis of O-glycosides and N-, C-glycosyl molecules with promising antidiabetic potential. Articles published after 2000 are included. First, the O-glycosides used in the treatment of diabetes are presented, followed by the N-glycosides and finally the C-glycosides constituting the largest group of antidiabetic drugs are described. Within each group of glycosides, we presented how the structure of compounds representing potential drugs changes and when discussing chemical compounds of a similar structure, achievements are presented in the chronological order. C-Glycosyl compounds mimicking O-glycosides structure, exhibit the best features in terms of pharmacodynamics and pharmacokinetics. Therefore, the largest part of the article is concerned with the description of the synthesis and biological studies of various C-glycosides. Also N-glycosides such as N-(β-D-glucopyranosyl)-amides, N-(β-D-glucopyranosyl)-ureas, and 1,2,3-triazolyl derivatives belong to the most potent classes of antidiabetic agents. In order to indicate which of the compounds presented in the given sections have the best inhibitory properties, a list of the best inhibitors is presented at the end of each section. In summary, the best inhibitors were selected from each of the summarizing figures and the results of the ranking were placed. In this way, the reader can learn about the structure of the compounds having the best antidiabetic activity. The compounds, whose synthesis was described in the article but did not appear on the figures presenting the structures of the most active inhibitors, did not show proper activity as inhibitors. Thus, the article also presents studies that have not yielded the desired results and show directions of research that should not be followed. In order to show the directions of the latest research, articles from 2018 to 2019 are described in a separate Sect. 5. In Sect. 6, biological mechanisms of action of the glycosides and patents of marketed drugs are described.

Indexed as

AnimalsDiabetes MellitusDrug DiscoveryEnzyme InhibitorsGlycogen PhosphorylaseGlycosidesHumansHypoglycemic AgentsProtein Tyrosine Phosphatase, Non-Receptor Type 1Sodium-Glucose Transporter 2 InhibitorsStructure-Activity RelationshipEnzyme InhibitorsGlycogen PhosphorylaseGlycosidesHypoglycemic AgentsProtein Tyrosine Phosphatase, Non-Receptor Type 1Sodium-Glucose Transporter 2 InhibitorsC-GlycosidesDiabetes type 2Glycogen phosphorylase inhibitorN-GlycosidesO-GlycosidesSodium-dependent glucose cotransporter inhibitor

Identifiers

PMID31165274
PMCPMC6548768
OpenAlexW2956264639

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.